June 17, 2024
Plasma Protease C1-Inhibitor Treatment Market

The Growing Plasma Protease C1-inhibitor Treatment Market is in Trends by Increasing Prevalence of Hereditary Angioedema

The plasma protease C1-inhibitor treatment market comprises products that are used to treat hereditary angioedema (HAE), a rare genetic disorder characterized by spontaneous and recurrent episodes of swelling (edema) in various body parts like hands, feet, intestines, larynx, etc. C1-inhibitor protein concentrates inhibit the proteins responsible for inflammation and swelling. The global demand for plasma protease C1-inhibitor treatment has increased significantly owing to the rising prevalence of HAE across the world.

The Global Plasma Protease C1-inhibitor Treatment Market is estimated to be valued at US$ 6257.99 Bn in 2024 and is expected to exhibit a CAGR of 6.7% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the plasma protease C1-inhibitor treatment are R&D. Koninklijke Philips N.V., Panasonic Corporation, and Procter & Gamble. These major players are focusing on new product launches and expansion strategies to strengthen their global presence.

The growing awareness about hereditary angioedema and its treatment options has fueled the demand for Plasma Protease C1-Inhibitor Treatment Market Size products across the world. According to disease advocacy organizations, HAE affects approximately 1 in 10,000-50,000 people globally.

The manufacturers are expanding their operations in developing economies like Asia Pacific and Latin America owing to increased healthcare investments by various governments. Moreover, the lack of substitutes for plasma protease C1-inhibitor treatment in these emerging countries presents lucrative opportunities for market players.

Market key trends

The increasing research activities for development of longer acting C1-inhibitor concentrate for HAE prophylaxis is one of the key trends in the plasma protease C1-inhibitor treatment market. Currently available C1-inhibitor products offer protection for relatively short duration. Pharmaceutical companies are engaged in clinical trials for once-every-two-week and once-a-month subcutaneous C1-inhibitor prophylaxis to address the unmet needs of patients. This could help improve the access and patient adherence to treatment over the forecast period.

Porter’s Analysis

Threat of new entrants: The biotechnology involved in developing plasma protease C1-inhibitor treatments acts as a barrier to entry for new companies.

Bargaining power of buyers: Individual patients have little bargaining power for specialist and rare plasma protease C1-inhibitor treatments.

Bargaining power of suppliers: There are only a limited number of plasma fractions suppliers with facilities to develop and produce plasma protease C1-inhibitor treatments.

Threat of new substitutes: There are currently no effective substitute therapies for hereditary angioedema except for plasma protease C1-inhibitor treatments.

Competitive rivalry: Competition is high between the major participants in the plasma protease C1-inhibitor treatment market who continually invest in R&D to develop more effective therapies.

The geographical region where the value of the plasma protease C1-inhibitor treatment market is currently concentrated is North America. This is due to high per capita healthcare expenditures and the presence of major market players in countries such as the United States. However, the Asia Pacific region excluding Japan is poised to be the fastest growing market during the forecast period. This is because of increasing healthcare investments, growing medical tourism, and rising disposable incomes in emerging economies like China and India.

*Note:
1.Source: Coherent Market Insights, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it